文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

阿根廷2014-15年按WHO新方法开展的HIV-1治疗前耐药监测研究

Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15.
PubMed 文献 · J Antimicrob Chemother · 2016-10-26

全人群耐药突变患病率为14%±4%,NNRTI类为11%,最常见突变为K103N;无既往暴露者患病率为13%±4%。结论提示NNRTI耐药水平令人担忧,将促使指南改为启动ART前全员耐药检测。

要点

  • 全人群治疗前耐药突变患病率14%±4%,NNRTI类达11%。
  • 无既往抗逆转录病毒暴露者耐药突变患病率13%±4%。
  • 最常见突变为K103N,阿根廷将改为启动ART前全员耐药检测。

核心结论

  • 阿根廷起始ART人群存在令人担忧的HIV耐药水平,尤其对NNRTI类。
  • 基于该发现,阿根廷卫生部指南将改为建议所有人在启动ART前进行耐药检测。

研究设计与样本

  • 纳入至少330例18岁以上起始或重启ART者,以5%CI估算耐药相关突变点患病率。
  • 样本用Trugene处理,并以Stanford算法分析。

主要发现

  • 2014年8月至2015年3月共获得330例起始ART者的样本。
  • 平均±SD年龄35±11岁,男性63.4%,16.6%有既往抗逆转录病毒暴露,CD4中位数(IQR)275 cells/mm3(106-461)。
  • 全人群耐药突变患病率14%±4%(NRTI-RAMs 3%;NNRTI-RAMs 11%;PI-RAMs 2%)。
  • 无既往抗逆转录病毒暴露者耐药突变患病率13%±4%(NRTI 3%、NNRTI 10%、PI 2%)。
  • 最常见突变为K103N。

临床怎么用

  • 在阿根廷等NNRTI耐药传播水平较高地区,启动ART前应进行耐药检测以指导方案选择。
  • 若耐药检测落实到位,亦可作为持续耐药监测工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. OBJECTIVES: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHO-proposed methodology. METHODS: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. RESULTS: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean ± SD age was 35 ± 11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2% PI-RAMs) and 13% (±4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. CONCLUSIONS: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina's Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bissio E, Barbás MG, Bouzas MB, et al. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15. J Antimicrob Chemother. 2016. PMID: 27789684. doi:10.1093/jac/dkw445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。